Sensus Healthcare (NASDAQ:SRTS) Announces Earnings Results

Sensus Healthcare (NASDAQ:SRTS) announced its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03), FiscalAI reports. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The firm had revenue of $6.00 million during the quarter, compared to analyst estimates of $6.61 million.

Here are the key takeaways from Sensus Healthcare’s conference call:

• Sensus said physician conversations are shifting from explaining reimbursement to discussing adoption, following the Jan. 1 launch of dedicated CPT codes. Management also expects a proposed 26% increase in certain hospital-based SRT delivery codes to take effect Jan. 1, 2027, though that remains a forward-looking expectation.
• The company shipped 26 systems in Q3, including eight delayed from Q2, and secured initial purchases or Fair Deal agreements with two private equity-backed dermatology groups whose combined footprint is about 450 practices. Management sees potential to expand within those groups, but noted that converting the pipeline remains the priority.
• Q3 revenue fell 13% year over year to $6.0 million, reflecting a mix shift toward lower-priced SRT-100 systems and no sales to the historically largest customer. Cash, restricted cash, and equivalents declined to $12.9 million from $15.2 million at June-end.
• Profitability measures were mixed: gross margin improved to about 55% from 39%, and adjusted EBITDA loss narrowed to $1.5 million from $2.4 million, while net loss widened to $1.5 million from $0.9 million; the prior-year quarter included a $1.5 million tax benefit. Sensus is also developing recurring revenue through Fair Deal, Sensus Link, software, and services, but did not quantify their current contribution.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS opened at $3.22 on Friday. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.49. The business has a 50-day moving average price of $3.00 and a two-hundred day moving average price of $3.46.

Wall Street Analysts Forecast Growth

SRTS has been the topic of a number of recent analyst reports. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.83.

Insider Buying and Selling at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta bought 37,537 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were bought at an average price of $3.44 per share, for a total transaction of $129,127.28. Following the acquisition, the director directly owned 267,480 shares of the company’s stock, valued at approximately $920,131.20. This trade represents a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders bought 120,171 shares of company stock valued at $405,230. 10.20% of the stock is owned by corporate insiders.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin. Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.